ReviewBioImpacts : BI2025
Exosomes-derived mesenchymal stem cells in corneal regeneration: Properties and challenges.
Review in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Macrophages Heal and When They Scar: Timing in Corneal Fibrosis.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of mesenchymal stem cell (MSC) therapy has grown rapidly over the last ten years. MSCs' regenerative, and immunomodulatory properties have led to extensive research into them as therapeutic agents for the cell-based management of chronic ocular diseases. However, poor biocompatibility, penetration, and transport to the target ocular tissues restrict the use of MSC-based treatment. The involvement of exosomes in MSC biological functions has been clarified by a growing body of research, which also indicates that MSC-derived extracellular vesicles (EVs) have similar anti-inflammatory, anti-apoptotic, tissue-repairing, neuroprotective, and immunomodulatory qualities as MSCs. Recent developments in exosomes produced from MSCs may help address the difficulties MSC therapy faces. MSC-derived exosomes' nanoscale size enables them to quickly cross biological barriers and enter immune-privileged organs. This enables the effective delivery of therapeutic factors, like trophic and immunomodulatory agents, to ocular tissues that are normally difficult for both conventional therapy and MSC transplantation to target. Furthermore, mesenchymal stem cell transplantation hazards are reduced when EVs are used. The properties of EVs produced by MSCs and their biological roles in corneal regeneration are the main topics of this review of the literature.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.